Bimal Shah
Directeur/Bestuurslid bij ANEBULO PHARMACEUTICALS, INC.
Actieve functies van Bimal Shah
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ANEBULO PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 05-10-2023 | - |
| Independent Dir/Board Member | 05-10-2023 | - | |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Financieel Directeur/CFO | 05-09-2012 | - |
| Treasurer | 05-09-2012 | - |
Loopbaan van Bimal Shah
Eerdere bekende functies van Bimal Shah
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-06-2010 | 01-01-2021 |
Opleiding van Bimal Shah
| Stanford University | Graduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 5 |
Operationeel
| Corporate Officer/Principal | 1 |
| Director of Finance/CFO | 1 |
| Treasurer | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
| ANEBULO PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
- Beurs
- Insiders
- Bimal Shah
- Ervaring
